Daniel J Drucker (@danieljdrucker) 's Twitter Profile
Daniel J Drucker

@danieljdrucker

A clinician scientist at LTRI @sinaihealth studying GLP-1, diabetes, obesity and the gut endocrine system Proud 🇨🇦Not going anywhere Am 🇮🇱Chai

ID: 292334056

linkhttp://glucagon.com calendar_today03-05-2011 13:51:01

31,31K Tweet

32,32K Takipçi

1,1K Takip Edilen

Daniel J Drucker (@danieljdrucker) 's Twitter Profile Photo
Daniel J Drucker
@danieljdrucker

7 months ago

The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease U.S. FDA Novo Nordisk US

The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease <a href="/US_FDA/">U.S. FDA</a> <a href="/novonordiskus/">Novo Nordisk US</a>